Xeris Pharmaceuticals has selected the specialty pharmacy PANTHERx Rare to distribute Recorlev (levoketoconazole), the company’s therapy that was recently approved to treat adults with endogenous Cushing’s syndrome in whom surgery is not possible or not effective. “PANTHERx is proud to partner with Xeris to address the needs of adults with endogenous Cushing’s syndrome,” Rob Snyder, president of PANTHERx, said in a press release. “As the sole pharmacy for Recorlev, PANTHERx recognizes the importance of outstanding execution…

You must be logged in to read/download the full post.